Alan Glanville, Professor of Medicine, University of New South Wales; Director of Thoracic Medicine, St Vincent's Hospital, Sydney, Australia
Professor Allan R Glanville, MB BS,MD, FRACP trained in Sydney, Australia; Brompton Hospital, London, UK; and Stanford University, California, USA. Now he is conjoint professor of medicine at UNSW and is on the editorial boards of the American Journal of Respiratory and Critical Care Medicine, the American Journal of Transplantation, the Journal of Heart and Lung Transplantation, and Seminars in Respiratory and Critical Care Medicine. Prof Glanville is Past President of the International Society for Heart and Lung Transplantation and Programme Chair for the 2013 Annual Scientific Meeting in Montreal, Canada; Past Chair of the European and Australian Investigators in Lung Transplantation; and has authored over 200 publications including investigator driven global trials of immunosuppression and of novel therapies for RSV using small mRNAi. He is senior author of the 2015 International Consensus Guidelines for the Selection of Lung Transplantation Candidates, the joint ATS/ERS/JHLT BOS Guidelines, and the 2016 Pulmonary Antibody Mediated Rejection Consensus Report of the ISHLT. In Australia he is a foundation director of Outcomes Australia, a foundation member of ShareLife Australia, and a scientific advisor to Lymphangioleiomyomatosis Australia Research Alliance which complements work with international LAM groups and as a member of the Rare Lung Diseases Consortium. Ongoing research interests include definition of chronic lung allograft dysfunction phenotypes, definition of the translational aspects of the respiratory virome, therapeutic strategies for community acquired respiratory viral infections in the immune suppressed host, pathogenesis and management of antibody mediated lung allograft rejection, and innovative antifibroproliferative therapies for idiopathic pulmonary fibrosis. He is President elect of the Thoracic Society of Australia and New Zealand and Transplantation Head of the Australian IPF Consortium. He has performed numerous chair and mentor roles to facilitate global awareness and development of a critical mass of trained clinicians to solve problems which beset the lung allograft.
« Go Back